Scientific Reports · 2017 · 38 citations · 35 references
Life SciencesCardiologyMolecular BiologyCell SignalingInnate ImmunitySignal TransductionCardiovascular DiseaseCardiovascular Molecular PhysiologyInflammatory SignalingCardiac Hypertrophy SignalingInflammation In Cardiovascular DiseaseMyeloid Differentiation SignalingNf-κb SignalingRadioprotective AgentsRadioprotective EffectsRadioprotective MechanismsToll-like Receptor Signaling
Myeloid differentiation 1 (MD-1), a secreted protein interacting with radioprotective 105 (RP105), plays an important role in Toll-like receptor 4 (TLR4) signalling pathway. Previous studies showed that MD-1 may be restricted in the immune system. In this study, we demonstrated for the first time that MD-1 was highly expressed in both human and animal hearts. We also discovered that cardiac-specific overexpression of MD-1 significantly attenuated pressure overload-induced cardiac hypertrophy, fibrosis, and dysfunction, whereas loss of MD-1 had the opposite effects. Similar results were observed for in vitro angiotensin II-induced neonatal rat cardiomyocyte hypertrophy. The antihypertrophic effects of MD-1 under hypertrophic stimuli were associated with the blockage of MEK-ERK 1/2 and NF-κB signalling. Blocking MEK-ERK 1/2 signalling with a pharmacological inhibitor (U0126) greatly attenuated the detrimental effects observed in MD-1 knockout cardiomyocytes exposed to angiotensin II stimuli. Similar results were observed by blocking NF-κB signalling with a pharmacological inhibitor (BAY11-7082). Our data indicate that MD-1 inhibits cardiac hypertrophy and suppresses cardiac dysfunction during the remodelling process, which is dependent on its modulation of the MEK-ERK 1/2 and NF-κB signalling pathways. Thus, MD-1 might be a novel target for the treatment of pathological cardiac hypertrophy.
35
Kathrin S. Michelsen, Michelle Wong, Prediman K. Shah et al. · Proceedings of the National Academy of Sciences · 2004 · 1K citations · Full text